SLC29A1 Antibody, FITC conjugated

文獻引用 (1) 說明書

中文名稱：

SLC29A1兔多克隆抗體, FITC偶聯
貨號：

CSB-PA857875LC01HU
規格：

￥880
其他：

產品詳情
產品評價
引用文獻
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) SLC29A1 Polyclonal antibody
Uniprot No.：

Q99808
基因名：

SLC29A1
別名：

Equilibrative NBMPR-sensitive nucleoside transporter antibody; equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter antibody; Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter antibody; Equilibrative nucleoside transporter 1 antibody; es-type antibody; MGC1465 antibody; MGC3778 antibody; Nucleoside transporter antibody; Nucleoside transporter, es-type antibody; OTTHUMP00000016506 antibody; OTTHUMP00000016507 antibody; OTTHUMP00000016508 antibody; OTTHUMP00000016509 antibody; OTTHUMP00000016510 antibody; OTTHUMP00000016511 antibody; OTTHUMP00000016512 antibody; S29A1_HUMAN antibody; Slc29a1 antibody; solute carrier family 29 (equilibrative nucleoside transporter), member 1 antibody; solute carrier family 29 (nucleoside transporters), member 1 antibody; Solute carrier family 29 member 1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Equilibrative nucleoside transporter 1 protein (228-291AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

FITC
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

引用文獻

A drug delivery platform using engineered MUC1‐targeting exosomes enhances chemosensitivity and immunogenic cell death in pancreatic ductal adenocarcinoma H Jin,/,2024

產品評價

靶點詳情

功能：

Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
基因功能參考文獻：
1. CD73-depedent elevation of plasma adenosine signaling via ADORA2B-mediated protein kinase A phosphorylation, ubiquitination and proteasome degradation of erythrocyte ENT1 is a novel feed-forward signaling network underlying initial hypoxic adaptation and retention upon re-exposure. PMID: 28169986
2. FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) at the protein level rather than the transcriptional level. PMID: 28765935
3. ENT1 is a prognostic marker for pT2 gallbladder cancer (GBC) patients. PMID: 26266900
4. FLT3 has a role in cytarabine transport by SLC29A1 in pediatric acute leukemia PMID: 27391351
5. rs760370 SNP cannot serve as predictor of response in chronic HCV patients treated with interferon ribavirin therapy. PMID: 28207300
6. Glycosylation at N48 is critical for the localization, function and oligomerization of hENT1. PMID: 27480168
7. The combination of ENT1, MATE1 and OCT2 SNPs may serve as a predictive and prognostic marker in metastatic colorectal carcinoma patients treated with TAS-102. PMID: 28992563
8. CYR61 negatively regulates the nucleoside transporters hENT1 and hCNT3 in pancreatic ductal adenocarcinoma. PMID: 27604902
9. Chronic inhibition of ENT1 or by genetic removal of ENT1 enhanced the survival of R6/2 mice. Collectively, adenosine homeostasis and ENT1 expression are altered in Huntington's disease (HD). The inhibition of ENT1 can enhance extracellular adenosine level and be a potential therapeutic approach for treating HD. PMID: 28069792
10. hENT1 expression could predict gemcitabine efficacy in leiomyosarcoma and angiosarcoma patients, and if confirmed in prospective trials, these data would allow a better patient selection and an improvement in therapeutic efficacy. PMID: 28641307
11. studies describe 2 novel modes of action of ticagrelor, inhibition of platelet ENT1 and inverse agonism at the P2Y12R that contribute to its effective inhibition of platelet activation. PMID: 27694321
12. Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. These results validate hENT1 as a bona fide target for potential drug target and serve as a useful basis for future biophysical and structural studies. PMID: 27995448
13. These findings suggest that ENT1 is regulated via receptor-dependent calcium-linked pathways resulting in an alteration of purine flux, which may modulate purinergic signaling and influence NA drug efficacy. PMID: 27009875
14. SLC29A1 rs760370 and KLF12 rs9543524 SNPs are associated with treatment induced thrombocytopenia in chronic hepatitis C patients treated with PEGIFN2b/ribavirin/combination. PMID: 26750805
15. interaction of Met(33) (involved in dipyridamole binding) with BCR-ABL inhibitors and reduced interaction with M33A mutant hENT1. PMID: 27432881
16. Authors clearly demonstrate that ribavirin uptake in primary human hepatocytes is variable and correlates with ENT1 expression. PMID: 28417642
17. A pro-apoptotic effect of verapamil was observed in L3.6pl cells, but not in L3.6plGres cells, which was linked to their differential expression of P-gp and equilibrative nucleoside transporter-1 (ENT-1). PMID: 27177126
18. Human ENT1 proteins exist as two sub-populations, and cytidine pre-treatment leads to the internalization of one population. PMID: 27906634
19. The mRNA expression levels of the human equilibrative transporter-1 (hENT1) were significantly down-regulated under hypoxia, but treatment with NHI-1 was associated with a recovery of hENT1 expression. PMID: 27906635
20. Results showed that both SLC29A1 and SLC29A2 were expressed at lower levels in colon cancer cell lines originating from metastatic sites than from primary sites. PMID: 28218790
21. Direct evidence for apical localization of ENT1 and integral expression of ENT2 in intestinal epithelial cells. PMID: 27160886
22. mRNA expression of ENT1 was closely associated with cell proliferation and varied in seven non-Hodgkin lymphoma cell lines. PMID: 27173327
23. Data show that equilibrative nucleoside transporter (hENT1) expression was an independent prognostic factor in both whole patients and those with resection. PMID: 26784908
24. Low ENT1 expression is associated with periampullary adenocarcinoma. PMID: 26362587
25. High expression of hENT1 appears to predict a good response to decitabine and a prolonged survival in higher-risk myelodysplastic syndrome patients treated with decitabine. PMID: 26944860
26. Studies indicate that an autophagy response induced by hepatitis C virus (HCV) in a cell culture reduces ribavirin (RBV) uptake and antiviral activity by diminishing the surface expression of nucleoside transporters) member 1 (ENT1). PMID: 26431496
27. The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in Ribavirin dosing during hepatitis C virus therapy with direct acting antiviral agents PMID: 26279293
28. The Role of Flexible Loops in Folding, Trafficking and Activity of Equilibrative Nucleoside Transporters. PMID: 26406980
29. RECPAM analysis showed that DCK and CHOP were most relevant variables for the identification of patients with different mortality risk, while hENT1 and CHOP were able to identify subgroups of patients with different disease progression risk PMID: 25199538
30. ENT1 expression profile did not serve as a useful prognostic biomarker and therapeutic target for surgically resected patients with ampullary carcinoma. PMID: 25906447
31. Adenosine A1 receptor activation increases ENT1 activity via protein kinase C. PMID: 25725289
32. Brains from patients with drug-resistant temporal lobe epilepsy had higher levels of ENT1 than controls. PMID: 25490964
33. Acute myeloid leukemia patients with low activity of SLC29A1 genotype have shorter disease-free and overall survival in Ara-C based therapy. PMID: 25398670
34. SNPS in SLC29A1 were not associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
35. results establish Augustine as a new blood group system and place SLC29A1 as a new candidate gene for idiopathic disorders characterized with ectopic calcification/mineralization. PMID: 25896650
36. Human equilibrative nucleoside transporter 1c1 and d3 (and c2) mRNAs are primarily expressed in human hepatocytes, which suggests that they may play important roles in controlling hENT1 expression levels in those cells. PMID: 24522200
37. meta-analysis suggests that high hENT1 expression may be associated with improved OS and DFS of pancreatic cancer patients treated with gemcitabine PMID: 24625353
38. High intratumoural hENT1 and low RRM1 expression were independently associated with prolonged disease-free survival in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 25032731
39. Study found no evidence supporting the use of hENT1 as a predictive biomarker for gemcitabine efficacy in patients with advanced pancreatic cancer. PMID: 24857044
40. A low human equilibrative nucleoside transporter1 level represents a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy. PMID: 24475233
41. potential prognostic and predictive role of SLC29A1 has been demonstrated for selected subset of patients--{REVIEW} PMID: 24280569
42. Studies indicate that high expression of nucleoside transporter subunits 1 (hENT1) in pancreaticobiliary (PB) cancer patients receiving GEM-based adjuvant therapy is associated with improved overall survival and disease-free survival. PMID: 24152955
43. Genetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of metastatic breast cancer patients treated with paclitaxel-gemcitabine chemotherapy. PMID: 24361227
44. findings implicate ENT1 in liver protection from ischemia and reperfusion injury and suggest ENT inhibitors may be of benefit in the prevention or treatment of ischemic liver injury PMID: 23703920
45. Studies indicate that HENT1 and SPARC expression seem to be useful predictive factors of response to chemotherapy in pancreatic cancer. PMID: 23846918
46. these findings reveal the transcriptional repression of ENT1,2 as an innate protective response during acute pulmonary inflammation. PMID: 23590299
47. hENT1 and Notch3 mRNA expressions in biopsy specimens were the key predictive biomarkers of gemcitabine effect and gemcitabine sensitivity in patients with unresectable pancreatic ductal carcinoma. PMID: 23492684
48. Data suggest that SLC29A1 is located on basolateral membrane of adult Sertoli cells; SLC29A1 is primarily responsible for basolateral nucleoside uptake into Sertoli cells. In contrast, SLC29A2 is localized to apical membrane of Sertoli cells. PMID: 23639800
49. It was confirmed that wild-type for single nucleotide polymorpismss rs6932345 and rs747199 showed higher SLC29A1 mRNA expression in peripheral blood mononuclear cells. PMID: 23095574
50. ENT1-mediated uptake of gemcitabine might compensate for the total uptake of gemcitabine; therefore, the variation in the apparent accumulation of gemcitabine is smaller than that of the individual transporters. PMID: 22644860
顯示更多

收起更多
亞細胞定位：

Basolateral cell membrane; Multi-pass membrane protein. Apical cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein. Note=Predominantly localized in the basolateral membrane in polarized MDCK cells.
蛋白家族：

SLC29A/ENT transporter (TC 2.A.57) family
組織特異性：

Detected in erythrocytes (at protein level). Expressed in heart, brain, mammary gland, erythrocytes and placenta, and also in fetal liver and spleen.
數據庫鏈接：

HGNC: 11003

OMIM: 602193

KEGG: hsa:2030

STRING: 9606.ENSP00000360773

UniGene: Hs.25450

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human